{"id":55745,"date":"2023-04-12T16:07:30","date_gmt":"2023-04-12T14:07:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/"},"modified":"2023-04-12T16:07:30","modified_gmt":"2023-04-12T14:07:30","slug":"nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/","title":{"rendered":"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost"},"content":{"rendered":"
\n

\nEnLiSense CCM<\/b><\/a> Receives Funding from Crohn’s & Colitis Foundation To Develop Its Real-Time Inflammation Monitor Using Sweat Sensors For Tracking And Monitoring IBD Disease Activity In Patients<\/b><\/p>\n

<\/a><\/p>\n

DALLAS–(BUSINESS WIRE)–#Colitis<\/a>—EnLiSense CCM<\/a>, a medical health wearables technology company that non-invasively measures inflammatory biomarkers with sweat, announced today that it has received an investment from the Crohn\u2019s & Colitis Foundation\u2019s IBD Ventures program to develop EnLiSense CCM\u2019s IBD AWARE product. IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).<\/p>\n

\nThe IBD AWARE device and sensor rests on a patient\u2019s skin sampling nano-liters of passive sweat and will continuously measure and report biomarkers such as C-Reactive Protein (CRP), Calprotectin, Interleukin-6 (IL6), Tumor Necrosis Factor alpha (TNF-\u03b1), Interleukin-1 beta (IL1-\u03b2), Cortisol and other biomarkers. Additional details about the IBD AWARE platform and how it works can be found at https:\/\/www.ibdwearable.com<\/a>.<\/p>\n

\nFunding from the IBD Ventures program will support further clinical studies for the product development and validation with clinicians, David T. Rubin, M.D., of the University of Chicago Medicine and Bruce Sands, M.D. and Robert Hirten, M.D. of the Icahn School of Medicine at Mount Sinai. These studies will further the development of a critical diagnostic tool that can help enable research and development of personalized treatment and therapies to improve the quality of life for patients with IBD.<\/p>\n

\n\u201cMinimally invasive and real time monitoring of inflammation is a critical unmet need for patients with IBD,\u201d said Andres Hurtado-Lorenzo Ph.D., Vice President, Translational Research & IBD Ventures at the Crohn\u2019s & Colitis Foundation. \u201cWe are very enthusiastic about supporting EnLiSense clinical studies to further validate their groundbreaking sweat biosensor, following our initial academic investment in this technology via the Foundation\u2019s Novel Technologies Initiative. We are thrilled to see how the synergy of our investments is bridging the gap between academic and industry research to advance novel and highly needed bioengineering-based solutions for IBD patients.\u201d<\/p>\n

\n\u201cWe are proud to partner with the Crohn\u2019s & Colitis Foundation and our clinicians on this important endeavor,\u201d said Sriram Muthukumar Ph.D., CEO of EnLiSense CCM.<\/p>\n

\n\u201cIBD AWARE will provide patients and their clinicians with the real-time, actionable data they need to further quality of life outcomes. IBD AWARE biomarkers would be able to identify those individuals at risk for the disease and be disease specific; would be able to detect disease activity and monitor the effect of treatment; and would have a prognostic value towards relapse or recurrence,\u201d Muthukumar concluded.<\/p>\n

\nSince 2017, IBD Ventures has invested in 20 companies and academic institutions to advance new projects. The Crohn\u2019s & Colitis Foundation launched IBD Ventures to accelerate the discovery and development of research-based products with the potential to address unmet needs of IBD patients. As a venture philanthropy program, IBD Ventures aims to advance products through the developmental pathway towards patient care by investing in novel early-stage products. The program funds, advises, and provides resources to for-profit companies, academic institutions, and other organizations seeking to develop products that can improve remission rates and quality of life for patients with IBD. For more information, visit IBD Ventures online<\/b><\/a>.<\/p>\n

\nAbout the Crohn’s & Colitis Foundation<\/b><\/p>\n

\nThe Crohn’s & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD). The Foundation’s mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life for the millions of Americans living with IBD. For more information, visit www.crohnscolitisfoundation.org<\/a>, call 888-694-8872, or email info@crohnscolitisfoundation.org<\/a>.<\/p>\n

\nAbout EnLiSense CCM<\/b><\/p>\n

\nEnLiSense CCM is committed to developing medical wearables for enhancing the quality of human life with a focus on bringing to market for the product uses cases associated with Stress and Inflammation leading to long-term chronic health conditions that are CORTI and IBD AWARE, towards enabling the patient to take control and manage their health conditions based on their individualized disease states. Learn more about EnLiSense CCM products @ https:\/\/www.cortiwearable.com<\/a> and @ https:\/\/www.ibdwearable.com<\/a> or follow the company on LinkedIn<\/a> or email PR@enlisense.com<\/a>. For information on EnLiSense’s terms and conditions, visit our website<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nSriram Muthukumar
\n
PR@enlisense.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EnLiSense CCM Receives Funding from Crohn’s & Colitis Foundation To Develop Its Real-Time Inflammation Monitor Using Sweat Sensors For Tracking And Monitoring IBD Disease Activity In Patients DALLAS–(BUSINESS WIRE)–#Colitis—EnLiSense CCM, a medical health wearables technology company that non-invasively measures inflammatory biomarkers with sweat, announced today that it has received an investment from the Crohn\u2019s & … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55745","6":"format-standard","7":"category-industry"},"yoast_head":"\nNextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EnLiSense CCM Receives Funding from Crohn’s & Colitis Foundation To Develop Its Real-Time Inflammation Monitor Using Sweat Sensors For Tracking And Monitoring IBD Disease Activity In Patients DALLAS–(BUSINESS WIRE)–#Colitis—EnLiSense CCM, a medical health wearables technology company that non-invasively measures inflammatory biomarkers with sweat, announced today that it has received an investment from the Crohn\u2019s & ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-12T14:07:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230412005039\/en\/1760384\/21\/Logo_IBDAware.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost\",\"datePublished\":\"2023-04-12T14:07:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/\"},\"wordCount\":724,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005039\\\/en\\\/1760384\\\/21\\\/Logo_IBDAware.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/\",\"name\":\"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005039\\\/en\\\/1760384\\\/21\\\/Logo_IBDAware.jpg\",\"datePublished\":\"2023-04-12T14:07:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005039\\\/en\\\/1760384\\\/21\\\/Logo_IBDAware.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005039\\\/en\\\/1760384\\\/21\\\/Logo_IBDAware.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/","og_locale":"en_US","og_type":"article","og_title":"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost - Pharma Trend","og_description":"EnLiSense CCM Receives Funding from Crohn’s & Colitis Foundation To Develop Its Real-Time Inflammation Monitor Using Sweat Sensors For Tracking And Monitoring IBD Disease Activity In Patients DALLAS–(BUSINESS WIRE)–#Colitis—EnLiSense CCM, a medical health wearables technology company that non-invasively measures inflammatory biomarkers with sweat, announced today that it has received an investment from the Crohn\u2019s & ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-12T14:07:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230412005039\/en\/1760384\/21\/Logo_IBDAware.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost","datePublished":"2023-04-12T14:07:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/"},"wordCount":724,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230412005039\/en\/1760384\/21\/Logo_IBDAware.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/","url":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/","name":"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230412005039\/en\/1760384\/21\/Logo_IBDAware.jpg","datePublished":"2023-04-12T14:07:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230412005039\/en\/1760384\/21\/Logo_IBDAware.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230412005039\/en\/1760384\/21\/Logo_IBDAware.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nextgen-sensors-set-to-enable-real-time-ibd-disease-management-after-funding-boost\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55745"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55745\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}